# Apatinib for Metastatic Esophageal Cancer.

> **NCT02544737** · PHASE2 · UNKNOWN · sponsor: **Hangzhou Cancer Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Esophageal Cancer
- Metastatic Esophageal Cancer
- Apatinib

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT02544737
- **Lead sponsor:** Hangzhou Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2016-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544737, "Apatinib for Metastatic Esophageal Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02544737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*